RARE
Ultragenyx Pharmaceutical Inc.Recent alerts on RARE
All signals →
Insider trade
Sale by Horn Howard (Chief Financial Officer)
12h ago
News
Unveiling 14 Analyst Insights On Ultragenyx Pharmaceutical - Benzinga
14d ago
News
Leerink Partners upgrades Ionis stock on key asset commercialization - Investing.com
14d ago
Insider trade
Sale by SULIMAN SHEHNAAZ
14d ago
News
Ultragenyx (RARE) Posts New Data From Bone Disease Study
14d ago
News
Ultragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug
14d ago
News
Peeling Back The Layers: Exploring Ultragenyx Pharmaceutical Through Analyst Insights
14d ago
News
Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study
14d ago
SEC filing
RARE Stockholders Approve Third Amended 2023 Incentive Plan, Elect Class I Directors, Ratify Ernst & Young LLP as Auditor
14d ago
Insider trade
Sale by Eric Crombez (EVP and Chief Medical Officer)
26d ago
SEC filing
RARE Reports $136M Q1 Rev, $730-760M 2026 Guidance, Crysvita $93M, Dojolvi $18M, GTX-102 Phase 3 Data 2H26
27d ago
Insider trade
Sale by Howard Horn (Chief Financial Officer)
28d ago
News
Ultragenyx downgraded to neutral at Goldman Sachs on setrusumab data
69d ago
News
Mereo downgraded at JP Morgan on setrusumab regulatory uncertainty
70d ago
News
Ultragenyx posts late-stage trial win for gene therapy in urea cycle disorder
81d ago
SEC filing
RARE Announces Positive Phase 3 DTX301 Data: 18% Ammonia Reduction, 71% Much Improved, $150M Spend
82d ago
Scanner
Unusual buy pressure (5.2x avg, 75% up-volume, +3.9% / +0.85 intraday, above VWAP)
84d ago
Insider trade
Sale by John Richard Pinion (EVP, Chief Quality Operations Officer)
90d ago
Insider trade
Sale by Erik Harris (EVP & Chief Commercial Officer)
90d ago
Insider trade
Sale by Emil D Kakkis (President & CEO)
90d ago
Insider trade
Sale by Howard Horn (Chief Financial Officer)
90d ago
Insider trade
Sale by Eric Crombez (EVP and Chief Medical Officer)
90d ago
Insider trade
Sale by Karah Herdman Parschauer (EVP and Chief Legal Officer)
90d ago
Insider trade
Sale by Theodore Alan Huizenga (SVP, Chief Accounting Officer)
90d ago
SEC filing
RARE FDA Accepts BLA for DTX401 Gene Therapy, Grants Priority Review for GSDIa Treatment
98d ago
Get push alerts for RARE
Add it to your watchlist in the app and receive every signal the moment it fires.
Download for iOS